Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | completed | Phase 2 / Phase 3 | 130 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01951482 | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2025 |
| clinicaltrials |
| NCT02066454 | Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs(MYELAXAT) | completed | Phase 3 | 108 | University Hospital, GrenobleOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06597175 | Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy(ORIGO) | completed | Phase 3 | 300 | Olive HealthcareINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04206072 | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC | completed | Phase 2 / Phase 3 | 362 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 | clinicaltrials |
| NCT03159897 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | completed | Phase 3 | 500 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT00680901 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | completed | Phase 3 | 545 | Novartis PharmaceuticalsINDUSTRY | 23 | Aug 7, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT05137561 | Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)(PROBIOP) | completed | Phase 2 / Phase 3 | 217 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT00049595 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma | completed | Phase 3 | 552 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Aug 5, 2025 | clinicaltrials |
| NCT03575351 | A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas(TRANSFORM) | completed | Phase 3 | 184 | CelgeneINDUSTRY | 12 | Aug 3, 2025 | clinicaltrials |
| NCT03728881 | Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial(PRIMAVERA) | completed | Phase 3 | 1,240 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2025 | clinicaltrials |
| NCT00092534 | Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)(FUTURE II) | completed | Phase 3 | 12,167 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2025 | clinicaltrials |
| NCT00243867 | Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer | completed | Phase 3 | 518 | American Regent, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT02684006 | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | completed | Phase 3 | 886 | PfizerINDUSTRY | 21 | Jul 30, 2025 | clinicaltrials |
| NCT03434678 | Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection | completed | Phase 3 | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT02975934 | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON3) | completed | Phase 3 | 405 | pharmaand GmbHINDUSTRY | 12 | Jul 25, 2025 | clinicaltrials |
| NCT05458856 | Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate(TriptoSwitch) | completed | Phase 3 | 147 | IpsenINDUSTRY | 7 | Jul 25, 2025 | clinicaltrials |
| NCT00284778 | Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer | completed | Phase 3 | 150 | University Hospital, LimogesOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY | 27 | Jul 24, 2025 | clinicaltrials |
| NCT02059499 | Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions | completed | Phase 3 | 91 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 23, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT02358031 | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | completed | Phase 3 | 882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 18, 2025 | clinicaltrials |
| NCT03834506 | Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) | completed | Phase 3 | 1,030 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Jul 18, 2025 | clinicaltrials |
| NCT05547386 | 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 163 | Mayo ClinicOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT02451943 | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma(ANNOUNCE) | completed | Phase 3 | 509 | Eli Lilly and CompanyINDUSTRY | 25 | Jul 15, 2025 | clinicaltrials |
| NCT04742361 | Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer | completed | Phase 3 | 136 | ABX advanced biochemical compounds GmbHINDUSTRY | 3 | Jul 15, 2025 | clinicaltrials |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | completed | Phase 3 | 3,270 | National Cancer Institute (NCI)NIH | 4 | Jul 14, 2025 | clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT03534453 | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy(L-MOCA) | completed | Phase 3 | 229 | AstraZenecaINDUSTRY | 2 | Jul 10, 2025 | clinicaltrials |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission(QUAZAR AML-001) | completed | Phase 3 | 472 | CelgeneINDUSTRY | 23 | Jul 8, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT01815853 | Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer(Neo-CRAG) | completed | Phase 3 | 620 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03863860 | A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients | completed | Phase 3 | 252 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04616768 | PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers(PROStep) | completed | Phase 3 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma(MIRAGE) | completed | Phase 3 | 749 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Jul 1, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT02667587 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)(CheckMate548) | completed | Phase 3 | 716 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2025 | clinicaltrials |
| NCT01354522 | TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer | completed | Phase 3 | 204 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT03867175 | Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer | completed | Phase 3 | 5 | Wake Forest University Health SciencesOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT00769379 | Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy | completed | Phase 3 | 2,014 | National Cancer Institute (NCI)NIH | 4 | Jun 12, 2025 | clinicaltrials |
| NCT01804790 | Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer(Néofirinox) | completed | Phase 3 | 461 | UNICANCEROTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04100018 | A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer(CheckMate 7DX) | completed | Phase 3 | 1,030 | Bristol-Myers SquibbINDUSTRY | 28 | Jun 12, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2025source: clinicaltrials